How Long Nicotinamide Riboside Stays in Your System: What Studies Report

What "stays in your system" means for an NAD+ precursor

Nicotinamide riboside (NR) is not handled by the body the way a drug with a single measurable parent compound is. It is a pyridine nucleoside form of vitamin B3 that feeds the nicotinamide adenine dinucleotide (NAD+) pool, and reviews of NAD+ intermediates described NR and nicotinamide mononucleotide as precursors that are converted through salvage-pathway enzymes into NAD+ and its related metabolites (PMID 29249689). That matters for any "how long does it last" question, because three different clocks run at once: the residence of intact NR in circulation, the residence of its immediate breakdown products such as nicotinamide, and the slower turnover of the NAD+ pool inside tissues.

Most published human work measured the second and third of those clocks. The study by Trammell and colleagues characterised oral bioavailability by profiling the blood NAD+ metabolome rather than by reporting a terminal half-life for intact NR (PMID 27721479). Readers looking for a single clearance number will not find one in the literature summarised here, and this page does not supply one.

Is NR a peptide? A scope note on general versus compound-specific data

NR is a small molecule, not a peptide. General peptide pharmacokinetic principles — enzymatic proteolysis, short circulating half-lives measured in minutes, renal filtration of small fragments, depot behaviour after subcutaneous injection — are general background and are not compound-specific to NR. Everything stated below about NR doses, metabolite timelines and tissue findings is drawn from the NR and NAD+ literature cited in the same sentence. Where this page describes broader pharmacokinetic reasoning, it is labelled as such.

What human studies reported about timing

The most directly relevant human pharmacokinetic work reported that single oral doses of 100 mg, 300 mg and 1000 mg of NR produced dose-dependent increases in the blood NAD+ metabolome in healthy adults, with sampling across the 24 hours following administration (PMID 27721479). In the same work, researchers identified nicotinic acid adenine dinucleotide (NAAD) as a sensitive biomarker of effective NAD+ repletion, meaning that a metabolite other than NR itself carried the clearest and most durable signal of exposure (PMID 27721479). That study also reported that oral NR raised hepatic NAD+ in mice more effectively than equivalent amounts of nicotinic acid or nicotinamide, establishing NR as orally bioavailable in both species (PMID 27721479).

Repeat-dosing data extend the timeline. Elhassan and colleagues administered 1 g/day of NR for 21 days to aged men and reported augmentation of the skeletal muscle NAD+ metabolome, including elevated NAAD, alongside transcriptomic changes in energy-metabolism pathways and an anti-inflammatory signature in circulating cytokines (PMID 31412242). The study measured tissue during supplementation rather than after withdrawal, so it described accumulation of a metabolite signature over three weeks, not how quickly that signature decayed once dosing stopped (PMID 31412242).

Measured windows at a glance

Why blood levels and tissue levels run on different clocks

A recurring theme in this literature is that circulating precursor concentrations are a poor proxy for tissue NAD+ status. A pharmacokinetic study published in 2026 examined NAD augmentation in blood and brain following oral precursor supplementation, directly addressing whether a peripheral signal tracks a central one (PMID 41858901). In blood cells, researchers reported that NR raised platelet NAD levels during storage yet did not prevent the platelet storage lesion, an example of a measurable biochemical change in one compartment without the downstream functional change investigators were testing for (PMID 31652008).

Preclinical work shows how long tissue-level consequences can outlast an oral dose. A 2019 study reported that NR stimulated hematopoiesis in mice through increased mitochondrial clearance, a cellular process operating on a timescale of days rather than hours (PMID 30849366). Another reported that NR promoted autolysosome clearance in a model of doxorubicin-induced cardiotoxicity (PMID 31266854), and a separate model found that NAD+ together with Sirt5 restored mitochondrial bioenergetic failure and improved locomotor defects caused by sucla2 mutations (PMID 41574612). These are animal and cellular findings describing biology, not human clearance measurements.

Detectability and drug testing: what is and is not screened

Stated plainly: NR is a vitamin B3 derivative, and neither NR nor NAD+ is an analyte on standard workplace or clinical drug-screening panels, which target classes such as amphetamines, cocaine metabolites, opiates, phencyclidine and cannabinoids. Nothing in the cited literature describes NR being detected incidentally on such a panel.

Detection of NR exposure in research settings required purpose-built analytical chemistry. Researchers quantified NR-derived changes using targeted assays of the NAD+ metabolome and isotope-labelling approaches, which is how the dose-dependent blood response to 100, 300 and 1000 mg was resolved (PMID 27721479). NAAD emerged from that work as the biomarker most sensitive to repletion, and elevated muscle NAAD was likewise the clearest tissue signal after 21 days at 1 g/day (PMID 31412242). In sport, NAD+ precursors are vitamin-derived nutrients rather than listed doping agents; anti-doping status is set by the annually published prohibited list, not by the studies cited here.

Factors reported to change how long the signal persists

• Dose. The blood NAD+ metabolome response was dose-dependent across 100, 300 and 1000 mg single oral doses (PMID 27721479).
• Single dose versus repeat dosing. Repeated administration at 1 g/day for 21 days produced a tissue-level metabolome shift that single-dose blood sampling does not capture (PMID 31412242).
• Route and precursor identity. Reviews of NAD+ intermediates described distinct enzymatic routes by which NR, nicotinamide and nicotinic acid enter the NAD+ pool, which shapes where and how fast each is used (PMID 29249689).
• Tissue and cell type. Muscle, brain and platelets were assayed separately and behaved differently (PMID 31412242, PMID 41858901, PMID 31652008).
• Metabolic state. A review of altered NAD metabolism in metabolic disorders described disease-associated shifts in NAD+ synthesis and consumption that would alter baseline turnover (PMID 31078136).
• Chemical form. A reduced form of nicotinamide riboside was studied for protection of the cochlea against aminoglycoside-induced ototoxicity via SIRT1 activation, indicating that different NR forms are investigated as distinct chemical entities (PMID 35658237).

Tolerability and Adverse Events: What Studies Report

A PRISMA-guided systematic review of NAD+ supplementation for anti-aging and wellness synthesised the preclinical and clinical evidence base, including safety reporting across trials (PMID 41655607). In the 21-day human trial, researchers reported that 1 g/day of NR in aged men was accompanied by a reduction in circulating inflammatory cytokines and did not report a safety signal that halted the protocol (PMID 31412242). Single-dose human administration at 100, 300 and 1000 mg was likewise conducted without reported dose-limiting events in that pharmacokinetic study (PMID 27721479). Trial cohorts were small and short, so these observations describe what was measured, not long-term safety.

What the literature has not established

1. No numeric plasma or terminal half-life for intact NR in humans appears in the studies cited on this page (PMID 27721479).
2. Washout kinetics — how quickly NAAD and NAD+ return to baseline after supplementation stops — were not characterised in the 21-day muscle study (PMID 31412242).
3. Whether peripheral NAD changes reliably predict central nervous system changes was the explicit subject of dedicated blood-and-brain pharmacokinetic work rather than a settled conclusion (PMID 41858901).
4. Systematic review of the field emphasised heterogeneity across preclinical and clinical NAD+ supplementation studies (PMID 41655607).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any question concerning supplements, medications or laboratory testing.

Related reading

• Nicotinamide riboside: literature overview
• How long do peptides stay in your system?

References

• Nicotinamide riboside is uniquely and orally bioavailable in mice and humans (Nature Communications, 2016)
• Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD(+) Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures (Cell Reports, 2019)
• NAD(+) Intermediates: The Biology and Therapeutic Potential of NMN and NR (Cell Metabolism, 2018)
• The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation (iScience, 2026)
• NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence (Ageing Research Reviews, 2026)
• Implications of altered NAD metabolism in metabolic disorders (Journal of Biomedical Science, 2019)
• The senotherapeutic nicotinamide riboside raises platelet nicotinamide adenine dinucleotide levels but cannot prevent storage lesion (Transfusion, 2020)
• The NAD-Booster Nicotinamide Riboside Potently Stimulates Hematopoiesis through Increased Mitochondrial Clearance (Cell Stem Cell, 2019)
• Nicotinamide riboside promotes autolysosome clearance in preventing doxorubicin-induced cardiotoxicity (Clinical Science, 2019)
• A reduced form of nicotinamide riboside protects the cochlea against aminoglycoside-induced ototoxicity by SIRT1 activation (Biomedicine & Pharmacotherapy, 2022)
• NAD+ and Sirt5 restore mitochondrial bioenergetics failure and improve locomotor defects caused by sucla2 mutations (JCI Insight, 2026)